VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

Robert Dreicer, MD
Published: Monday, Mar 21, 2016



Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 makes for an interesting compound because, unlike many other therapies in the field, it is not androgen receptor (AR)-directed, Dreicer explains. The agent is approved before or after treatment with docetaxel for patients with predominant bone metastases. Because of this, it is a useful therapy for select patients.

Currently, researchers are questioning how to properly integrate radium-223 with AR therapies. Therefore, the optimal use of radium-223 in patients with mCRPC is not yet defined, Dreicer concludes.

<<< View more from 2016 New York GU



Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 makes for an interesting compound because, unlike many other therapies in the field, it is not androgen receptor (AR)-directed, Dreicer explains. The agent is approved before or after treatment with docetaxel for patients with predominant bone metastases. Because of this, it is a useful therapy for select patients.

Currently, researchers are questioning how to properly integrate radium-223 with AR therapies. Therefore, the optimal use of radium-223 in patients with mCRPC is not yet defined, Dreicer concludes.

<<< View more from 2016 New York GU


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x